Imunon’s (IMNN) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Imunon (NASDAQ:IMNN) in a research report sent to investors on Thursday morning,Benzinga reports. They currently have a $12.00 target price on the stock.

A number of other research analysts also recently issued reports on the company. EF Hutton Acquisition Co. I upgraded Imunon to a “strong-buy” rating in a report on Monday, September 23rd. D. Boral Capital reaffirmed a “buy” rating and set a $29.00 price target on shares of Imunon in a research report on Thursday.

Imunon Stock Down 2.8 %

Shares of NASDAQ:IMNN opened at $0.83 on Thursday. The firm has a market cap of $12.04 million, a price-to-earnings ratio of -0.44 and a beta of 2.12. Imunon has a 12 month low of $0.48 and a 12 month high of $3.65. The company’s fifty day simple moving average is $0.87 and its 200 day simple moving average is $1.07.

About Imunon

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.